Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (not Vivani Medical, Inc.) on February 22, 2016, reporting an event that occurred on February 16, 2016. The company is a California-based medical device firm focused on the Argus II Retinal Prosthesis System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical study results and does not contain financial statements.
Material Changes
The material event reported is the publication of positive 3-year results from the FLORA study in the journal Clinical And Experimental Optometry. The study assessed functional visual abilities in 26 blind patients using the Argus II system.
Outlook, Commentary, and Risks
- Study Results: The Functional Low-Vision Observer Rated Assessment (FLORA) indicated that 24 of 35 tasks (69%) showed statistically significant improvement with the Argus II device "ON" versus "OFF".
- Negative/Neutral Findings: Only two tasks (6%) showed a decrease in outcome, while nine tasks (26%) showed no significant change.
- Future Developments: Management stated that future enhancements will focus on external hardware improvements and software upgrades to benefit current users.
- Risks: The filing does not explicitly list new risks, though the study results are qualified by reference to the attached press release.
Investor Verification Checklist
- Verify the full text of the attached press release (Exhibit 99.1) for complete study details and limitations.
- Confirm the commercial impact of the Argus II system on the company's revenue pipeline.
- Review the company's latest 10-K or 10-Q for actual financial performance metrics not included in this 8-K.
- Assess the timeline for the mentioned hardware and software upgrades.